Malignant peritoneal effusion acting as a tumor environment in ovarian cancer progression: Impact and significance
暂无分享,去创建一个
[1] M. Pocard,et al. CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer , 2018, Molecular Cancer.
[2] A. Piché,et al. Ascites in Ovarian Cancer Progression: Opportunities for Biomarker Discovery and New Avenues for Targeted Therapies , 2017 .
[3] Anna Norberg,et al. How to make more out of community data? A conceptual framework and its implementation as models and software. , 2017, Ecology letters.
[4] Wang Min,et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. , 2016, The Journal of clinical investigation.
[5] E. Lengyel,et al. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells , 2016, Molecular Cancer Research.
[6] C. Rancourt,et al. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling , 2016, Molecular Cancer.
[7] C. Rancourt,et al. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions , 2016, Clinical & Experimental Metastasis.
[8] A. Sood,et al. Targeting the Tumor Microenvironment in Ovarian Cancer , 2016 .
[9] M. Ohmichi,et al. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. , 2015, Gynecologic oncology.
[10] Stephen T. C. Wong,et al. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. , 2015, American journal of physiology. Cell physiology.
[11] C. Rancourt,et al. Ovarian cancer ascites enhance the migration of patient‐derived peritoneal mesothelial cells via cMet pathway through HGF‐dependent and ‐independent mechanisms , 2015, International journal of cancer.
[12] H. Kleinman,et al. In Vitro Microtumors Provide a Physiologically Predictive Tool for Breast Cancer Therapeutic Screening , 2015, PloS one.
[13] C. Rancourt,et al. MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling. , 2015, American journal of cancer research.
[14] S. Kellouche,et al. Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins , 2014, Clinical & Experimental Metastasis.
[15] C. Morrison,et al. Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism , 2014, PloS one.
[16] D. Bachvarov,et al. Role of malignant ascites on human mesothelial cells and their gene expression profiles , 2014, BMC Cancer.
[17] Yan Zhou,et al. Effective Inhibition of c-MET-mediated Signaling, Growth, and Migration of Ovarian Cancer Cells is Influenced by the Ovarian Tissue Microenvironment , 2013, Oncogene.
[18] N. Ahmed,et al. Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research , 2013, Front. Oncol..
[19] S. Kaye,et al. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research , 2013, Nature Reviews Cancer.
[20] C. Rancourt,et al. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis , 2012, Molecular Cancer.
[21] E. Lengyel,et al. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. , 2012, The Journal of clinical investigation.
[22] Jing Cai,et al. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. , 2012, Carcinogenesis.
[23] C. Rancourt,et al. Profiling of cytokines in human epithelial ovarian cancer ascites. , 2012, American journal of cancer research.
[24] C. Rancourt,et al. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients , 2011, BMC Cancer.
[25] J. Malek,et al. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12 , 2011, International journal of cancer.
[26] C. Rancourt,et al. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation , 2010, Oncogene.
[27] R. Bristow,et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. , 2009, Anticancer research.
[28] G. Rice,et al. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. , 2009, Gynecologic oncology.
[29] B. Nelson,et al. The impact of T‐cell immunity on ovarian cancer outcomes , 2008, Immunological reviews.
[30] G. Coukos,et al. Immunotherapy opportunities in ovarian cancer , 2008, Expert review of anticancer therapy.
[31] A. Mes-Masson,et al. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids , 2008, BMC Genomics.
[32] C. Rancourt,et al. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer. , 2003, Cytotherapy.
[33] G. Mills,et al. The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.
[34] L. Karabon,et al. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity , 2000, British Journal of Cancer.